16May 2024
Belimumab Dose Reduction in SLE Patients Shows Varied Impact on Disease Activity

Belimumab Dose Reduction in SLE Patients Shows Varied Impact on Disease Activity

A study investigated dose reduction prevalence and its impact on disease activity control in systemic lupus erythematosus (SLE) patients treated with belimumab (BEL). Among 324 patients, dose reduction occurred in 8.9%, with most maintaining the reduced dose over time. While disease activity remained mostly stable, some patients experienced increased clinical or serologic activity post-reduction. Fewer patients required glucocorticoids at 12 months, though median doses were higher. The study suggests that BEL doses can be reduced without significant short-term changes in disease activity but recommends closer post-reduction monitoring to identify potential exacerbations.

  • #rheumatology

Like

Save

Share